
ETIZOLAM-0.25

Eticoni-0.25 is Novalab Group’s Etizolam 0.25mg tablet formulation, manufactured under strict WHO-GMP standards and offered to pharma professionals across India for PCD pharma franchise and third-party/contract manufacturing. Backed by DCGI-approved composition and quality-tested raw materials, Eticoni-0.25 is a trusted addition to any CNS/neuro-psychiatry product range, giving franchise partners a competitive, monopoly-basis business opportunity in the anti-anxiety segment.
| Attribute | Details |
|---|---|
| Brand Name | Eticoni-0.25 |
| Composition | Etizolam 0.25mg |
| Therapeutic Category | Anxiolytic / CNS (Anti-anxiety & short-term insomnia) |
| Dosage Form | Tablet |
| Packing | 6×5×10 Tablets |
| Manufacturing Standard | WHO-GMP, ISO-certified facility |
| Availability | PCD Pharma Franchise, Monopoly Basis, Third-Party Manufacturing |
| Prescription Status | Schedule H — for use by registered medical practitioner only |
| Marketed By | Novalab Group, Panchkula |
Eticoni-0.25 contains Etizolam 0.25mg and is prescribed by physicians for the short-term management of anxiety and sleep disturbances, as directed by a registered medical practitioner.
Yes. Novalab Group offers Eticoni-0.25 on a monopoly-basis PCD pharma franchise model across India, along with marketing support and promotional inputs.
Eticoni-0.25 is manufactured for Novalab Group at a WHO-GMP certified facility under strict quality control standards.
Yes, Novalab Group provides third-party/contract manufacturing services for Etizolam-based formulations, including Eticoni-0.25.
Yes, it is a Schedule H drug and should only be sold against a valid prescription from a registered medical practitioner.
We are a research-based pharmaceutical company. The mission of Novalab Healthcare is to improve the health of the Indian community by providing them with quality.
Copyright by © 2026 Novalab Healthcare | Marketing By Digify Ads
